Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
PHA121 is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist. Data from Phase 1 studies in healthy volunteers demonstrate rapid exposure and predictable linear pharmacokinetics, and inhibition of bradykinin-induced hemodynamic changes in a human bradykinin-challenge study. PHVS416, a softgel capsule formulation containing PHA121, is currently in Phase 2 clinical development for the on-demand treatment of HAE.
Pharvaris was founded in October 2015 by executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.
Jan 09, 2023Pharvaris Provides Regulatory, Clinical, and Corporate Updates
Dec 08, 2022Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update
Dec 08, 2022Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks
More events are coming soon.